Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer

Kun Liu¹, Tao Qian², Liming Tang¹*, Jie Wang¹, Haohua Yang¹ and Jun Ren¹

Abstract

Background: MicroRNA let-7i has been proven to be down-regulated in many human malignancies and correlated with tumor progression and anticancer drug resistance. Our study aims to characterize the contribution of miRNA let-7i to the initiation and malignant progression of locally advanced gastric cancer (LAGC), and evaluate its possible value in neoadjuvant chemotherapeutic efficacy prediction.

Methods: Eighty-six previously untreated LAGC patients who underwent preoperative chemotherapy and radical resection were included in our study. Let-7i expression was examined for pairs of cancer tissues and corresponding normal adjacent tissues (NATs), using quantitative RT-PCR. The relationship of let-7i level to clinicopathological characteristics, pathologic tumor regression grades after chemotherapy, and overall survival (OS) was also investigated.

Results: Let-7i was significantly down-regulated in most tumor tissues (78/86: 91%) compared with paired NATs (P < 0.001), and low levels of let-7i were significantly correlated with local invasion, lymphatic metastasis, and poor pathologic tumor response. Multivariate Cox regression analysis revealed that low let-7i expression was an unfavorable prognostic factor of OS (hazard ratio (HR) = 2.316, P = 0.024) independently of other clinicopathological factors, including tumor node metastasis (TNM) stage (HR = 3.226, P = 0.013), depth of infiltration (HR = 4.167, P < 0.001), and lymph node status (HR = 2.245, P = 0.037).

Conclusions: These findings indicate that let-7i may be a good candidate for use as a therapeutic target and a potential tissue marker for the prediction of chemotherapeutic sensitivity and prognosis in LAGC patients.

Keywords: Gastric cancer, MicroRNA let-7i, Neoadjuvant chemotherapy, Tumor response

Background

Despite its declining incidence in Western countries over the past 50 years, gastric cancer (GC) remains the second most frequently diagnosed cancer worldwide, with more than 600,000 deaths per year [1]. Complete resection of the primary tumor and involved lymph nodes (LNs) is considered the only potentially curative treatment for GC. However, the majority of GC patients present an advanced stage when diagnosed, and the 5-year survival rate is poor, even in patients receiving radical resection [2]. It has been confirmed that preoperative chemotherapy could improve progression-free and overall survival (OS) in patients with operable advanced GC [3]. However, like antibiotic-resistant bacteria, tumor cells often show intrinsic or acquired resistance to anticancer drugs, leading to inefficacy of chemotherapy. Although previous investigations have identified a variety of molecules associated with the initiation, progression, and drug response of GC, its precise molecular mechanisms remain unclear, and biologic markers with high sensitivity and specificity for the diagnosis and chemotherapeutic response prediction of GC are still lacking.

MicroRNAs (miRNAs) are naturally occurring, small, non-coding RNAs that mediate gene expression through complimentary binding of the 3′ untranslated regions
(UTRs) of target genes in both plants and animals [4]. The binding results in degradation of the mRNA and inhibition of translation [5]. More than 700 miRNA sequences have been revealed in the human genome in miRBase version 13.0, and this number is predicted to double because more miRNAs are awaiting experimental validation. It is now evident that miRNAs have very important regulatory functions in some basic biological processes, such as development, cellular differentiation, proliferation, and apoptosis. In addition, about 50% of miRNAs are located in cancer-associated genomic regions or at fragile sites [6], and they are frequently misexpressed or mutated in cancer patients and regarded as oncogenes or tumor suppressor genes [7-9]. Furthermore, increasing amounts of evidence indicate that miRNAs are associated with sensitivity or resistance to chemotherapeutic drugs, such as cisplatin or 5-fluorouracil in various cancer types [10-13].

Let-7 was originally identified in the nematode Caenorhabditis elegans as a regulator of developmental timing and cellular proliferation [14]. Subsequent work revealed that both its sequence and its function were highly conserved in mammals. As one of the first tumor suppressor miRNAs, let-7 has been proven to be down-regulated in many human malignancies and correlates with tumor progression and clinical prognosis [15-17]. Specifically, miRNA let-7i, a let-7 family member, was confirmed to play an important role in anticancer drug resistance in vivo and in vitro [13,18]. However, to our knowledge, no attention has been paid to the value of let-7i in neoadjuvant chemotherapeutic efficacy prediction in GC patients.

In this study, we compared let-7i expression in GC with non-tumor tissues, and analyzed its clinicopathologic value. In addition, we investigated the possibility of let-7i as a novel biomarker in predicting tumor response and OS in advanced GC patients treated with neoadjuvant chemotherapy and surgery.

Methods
Patients and samples
A total of 86 LAGC patients, who had been treated with preoperative chemotherapy and surgery from July 2005 to March 2007, were enrolled in our study. The median age at diagnosis was 59 years (range, 37 to 69 years). All patients received three cycles of neoadjuvant chemotherapy (FOLFOX 4) and a radical resection. Chemotherapy consisted of 85 mg/m² oxaliplatin on day 1, and 200 mg/m² bolus 5-Fu and a 22h infusion of 5-Fu 600 mg/m² on days 1 and 2 every other week. Curative resection was performed within 2 weeks after the last application of chemotherapy. Patient eligibility also required the fulfilment of the following criteria: age 18 to 70 years; clinical tumor stage T2-4, N1, or M0, according to the American Joint Committee for Cancer (AJCC) [19]; performance status of 0 or 1, based on the Eastern Cooperative Oncology Group (ECOG) criteria; no evidence of distant metastases; adequate hematologic, hepatic, renal, and cardiac function. Pretreatment staging procedures included physical examination, chest X-ray, abdominal computed tomography (CT) scan, and endoscopic ultrasonography. Histological grade was assessed according to the World Health Organization criteria. Patients were excluded if they had a previous or secondary malignancy, were pregnant, had active bleeding from the upper gastrointestinal tract, had uncontrolled and serious infection, or had previously undergone radiation therapy, chemotherapy, or immunotherapy. This study was approved by the medical ethics committee of our institution, and signed informed consent was obtained from all patients.

Tissue samples were obtained before and after treatment. Prior to neoadjuvant chemotherapy, pairs of primary gastric tumors and normal adjacent tissues (NATs) >3 cm from the cancer tissue) were collected by gastroscope biopsies from each patient. Biopsies were flash frozen and stored at −80°C in liquid nitrogen prior to analysis of let-7i expression. After operation, the patient’s response to chemotherapy was assessed histologically using resected tissue.

RNA extraction and quantitative real-time PCR
Total RNA from pretreatment GC and NAT biopsies was isolated using TRIzol® reagent (Invitrogen Corp, Carlsbad, CA, USA) according to the manufacturer’s instructions. RNA quality and quantity were assessed using a Bioanalyzer 2100 system (Agilent Technologies Inc. Santa Clara, CA, USA). The let-7i and RNA U6 (as an internal control) specific complementary DNA were synthesized from total RNA using gene-specific primers according to the TaqMan® miRNA assay protocol (Applied Biosystems, Foster City, CA, USA). Reverse transcription reactions contained 10 ng total RNA, 50 mmol/l stem-loop RT primer, 1 × RT buffer, 0.25 mmol/l each deoxynucleotide triphosphate (dNTP), 3.33 units/μl MultiScribe® reverse transcriptase and 0.25 units/μl RNase inhibitor in a total volume of 7.5 μl (Applied Biosystems). Reactions were incubated in a 96-well plate for 30 min at 16°C, flowed by 30 min at 42°C and 5 min at 85°C, and then held at 4°C.

Real-time polymerase chain reaction (RT-PCR) was performed using the 7500 real-time PCR system (Applied Biosystems). Reactions were carried out in 96-well plates in a total volume of 10 μl (0.67 μl RT products, 1 × TaqMan® Universal PCR master mix, and 1 μl TaqMan® miRNA assay primer and probe mix). The
reactions were incubated at 95°C for 10 min and then followed by 45 cycles of 95°C for 15 s and 60°C for 10 min. All samples were processed in triplicate. The threshold cycle (Ct) was defined as the fractional cycle number at which the fluorescence passed the fixed threshold. The amount of let-7i relative to U6 RNA was calculated using the equation $2^{-\Delta \Delta Ct}$ where $\Delta Ct = (Ct_{let-7i} - Ct_{U6})$. The fold change in let-7i expression between GC and NATs was determined by the $2^{-\Delta \Delta Ct}$ method, where $\Delta \Delta Ct = (Ct_{let-7i} - Ct_{U6})$ (in tumor samples) $- (Ct_{let-7i} - Ct_{U6})$ (in NATs) [20].

Pathologic response evaluation
After resection, all specimens were cross-sectioned serially at 0.5 cm intervals. Two pathologists blinded to let-7i expression reviewed the slides. The Becker score [21], based on an estimation of the percentage of residual tumor tissue in relation to the macroscopically identifiable tumor bed, was used to evaluate pathologic response. Tumor regression was classified into three grades, as follows: Grade 1, complete or subtotal regression (<10% residual tumor per tumor bed); Grade 2, partial tumor regression (10% to 50% residual tumor per tumor bed); and Grade 3, minimal or no tumor regression (>50% residual tumor per tumor bed). All patients with grade 1 or 2 regression were classified as responders, while grade 3 was defined as a pathologic non-responder.

Follow-up
Follow-up was performed at 3-month intervals for 1 year, then at 6-month intervals for 3 years, and yearly thereafter. Follow-up consisted of a physical examination, a complete blood count, liver function tests, serum tumor markers, and an abdominal and pelvic CT scan. The patients also underwent chest X-rays and gastroscopy every 6 months, regardless of their follow-up schedule. Survival time was calculated from the date of the first neoadjuvant chemotherapy to the date of death or the last follow-up.

Statistics
Statistical analysis was performed using SPSS®, version 17.0 (SPSS Inc., Chicago, USA) for Windows®. Comparisons of let-7i levels in GC versus NATs were made with the Wilcoxon matched-pairs test. Clinicopathological factors and let-7i levels were analyzed by one-way analysis of variance (ANOVA). The joint effect of covariates was examined using the Cox proportional hazard regression model. All tests were two-tailed, and the significance level was set at $P < 0.05$.

Results
Let-7i expression in GC tissues and its association with clinicopathological characteristics before chemotherapy
The result of quantitative RT-PCR verified that let-7i was significantly down-regulated in most tumor tissues (78/86; 91%) compared with the paired NATs ($P < 0.001$, Wilcoxon matched-pairs test, Figure 1), with a median fold change of 0.28-fold. Patient characteristics with respect to decreased let-7i expression are shown in Table 1. Low levels of let-7i correlated significantly with local invasion and lymphatic metastasis. No correlation was observed between let-7i level and other clinicopathological features, such as age, sex, tumor site, or cell differentiation.

Correlation between let-7i expression and tumor response and overall survival
According to the three-point pathologic regression grade system, 17 of the 86 specimens were classified as grade 1, 38 as grade 2, and 31 as grade 3. In total, 55 patients were categorized as pathologic responders and 31 as non-responders. Let-7i expression levels in pathologic responders were significantly higher than in non-responders ($P < 0.001$, Table 1).

At the time of scheduled analysis (January 2012), 9 of the 86 patients were still alive, and the other patients had already passed away. The median follow-up time was 35 months, ranging from 9 to 76 months. Aside from let-7i expression ($P = 0.016$, hazard ratio (HR) = 2.436), univariate Cox proportional hazard regression analysis revealed that tumor node metastasis (TNM) stage ($P = 0.003$, HR = 3.478), differentiation degree ($P = 0.029$, HR = 2.128), depth of infiltration ($P < 0.001$, HR = 5.691), and lymph node status ($P = 0.008$, HR = 2.936) were also predictive factors for prognosis.
of LAGC patients. Multivariate Cox proportional hazard regression analysis confirmed that low-level let-7i expression ($P = 0.024$, HR = 2.316) was an unfavorable prognostic factor independent of other clinicopathological factors, including TNM stage ($P = 0.013$, HR = 3.226), depth of infiltration ($P < 0.001$, HR = 4.167), and lymph node status ($P = 0.037$, HR = 2.245; Table 2).

**Discussion**

The discovery of miRNAs has substantially changed the view on gene regulation, and new findings over the past few years have catapulted miRNAs to the center stage of cancer molecular biology. In this study, we compared let-7i expression levels in GC with NATs. By using real-time RT-PCR, we found that let-7i was significantly down-regulated in cancer tissues. In addition, a low level of let-7i was closely correlated with local invasion and lymphatic metastasis. Our findings are in agreement with some previous studies. For example, aberrant expression of let-7 has been proven by a number of groups and in various types of tumors, such as cholangiocarcinoma [22], lung cancer [15], epithelial ovarian cancer [23], breast cancer [24], and colon cancer [17]. Reduced let-7 expression has also been associated with tumor progression and shortened postoperative survival in lung and ovarian cancer patients [15,16,23]. Taken together, these results may help to explain the important role of let-7i not only in tumor pathogenesis but also in cancer progression and invasion in GC patients.

Our study also revealed the potential value of let-7i in predicting pathologic tumor response and OS in GC patients following neoadjuvant chemotherapy for the first time. Compared with postoperative chemotherapy, neoadjuvant chemotherapy has some theoretical benefits, including down-staging the primary tumor so as to increase the likelihood of a curative resection and performing an early treatment to the possible distant micrometastases. However, the selection of appropriate patients who will benefit from chemotherapy is still a major challenge in oncology. If chemotherapy is ineffective, the patient is needlessly exposed to its adverse effects and quality of life can be diminished. While many studies show a correlation between miRNAs and carcinogenesis and cancer progression, a few also reveal a role for miRNAs in cancer chemoresistance. In terms of

---

Table 1 Relationship of miRNA let-7i expression level and clinicopathological features

| Factors                | Number of patients | Let-7i (Average fold change ± SD) | P value |
|------------------------|--------------------|-----------------------------------|---------|
| Age (years)            |                    |                                   |         |
| ≤59                    | 43                 | 0.33 ± 0.14                       | 0.388   |
| >59                    | 43                 | 0.26 ± 0.19                       |         |
| Sex                    |                    |                                   |         |
| Male                   | 57                 | 0.38 ± 0.35                       | 0.215   |
| Female                 | 29                 | 0.24 ± 0.16                       |         |
| Local invasion         |                    |                                   |         |
| T2                     | 19                 | 0.87 ± 0.71                       | <0.001  |
| T3                     | 35                 | 0.40 ± 0.25                       | 0.002 b |
| T4                     | 32                 | 0.13 ± 0.11                       |         |
| Lymphatic metastasis   |                    |                                   |         |
| N1                     | 33                 | 0.49 ± 0.44                       | 0.003   |
| N2                     | 53                 | 0.18 ± 0.15                       |         |
| Tumor site             |                    |                                   |         |
| Upper                  | 22                 | 0.35 ± 0.30                       | 0.262   |
| Middle                 | 30                 | 0.25 ± 0.23                       |         |
| Lower                  | 34                 | 0.30 ± 0.22                       |         |
| Cell grade             |                    |                                   |         |
| Poor                   | 60                 | 0.27 ± 0.18                       | 0.476   |
| Moderate               | 26                 | 0.32 ± 0.28                       |         |
| Pathologic tumor response|                  |                                   |         |
| Responder              | 55                 | 0.59 ± 0.46                       | <0.001  |
| Non-responder          | 31                 | 0.16 ± 0.10                       |         |

* Compared with T3 and T4; b Compared with T4.

Table 2 Univariate and multivariate Cox proportional hazard regression analyses of the relationship between miRNA let-7i levels, clinicopathological characteristics, and prognosis in LAGC patients

| Variable                             | Subset               | Hazard ratio | P value |
|--------------------------------------|----------------------|--------------|---------|
| **Univariate analysis (n = 86)**     |                      |              |         |
| Age                                  | ≥59 versus <59       | 0.665        | 0.205   |
| Sex                                  | Male versus female   | 0.715        | 0.313   |
| Let-7i level                         | Fold change          | 2.436        | 0.016   |
| TNM stage                            | II versus III        | 3.478        | 0.003   |
| Depth of infiltration                | T2 versus T3,4       | 5.691        | <0.001  |
| Differentiation degree               | Well-moderate versus poor | 2.128 | 0.029   |
| Site                                 | Distal, middle, or upper third | 0.779 | 0.347   |
| Lymph node metastasis                | N1 versus N2         | 2.936        | 0.008   |
| **Multivariate analysis (n = 86)**   |                      |              |         |
| Age                                  | ≥59 versus <59       | 0.622        | 0.356   |
| Sex                                  | Male versus female   | 0.576        | 0.463   |
| Let-7i level                         | Fold change          | 2.316        | 0.024   |
| TNM stage                            | II versus III        | 3.226        | 0.013   |
| Depth of infiltration                | T2 versus T3,4       | 4.167        | <0.001  |
| Differentiation degree               | Well to moderate versus poor | 0.798 | 0.166   |
| Site                                 | Distal, middle, or upper third | 0.535 | 0.572   |
| Lymph node metastasis                | N1 versus N2         | 2.245        | 0.037   |
let-7i, Blower et al. [18] reported that chemosensitivity of NCI-60 human cancer cell lines was increased or decreased when transfected with active let-7i precursor or anti-let-7i oligomer. Yang et al. [13] confirmed that let-7i expression was significantly reduced in chemotherapy-resistant ovarian cancer patients in comparison with chemotherapy-sensitive patients, and that up-regulated let-7i could increase the sensitivity of ovarian and breast cancer cells to cisplatinum. Further, the let-7 family could also alter sensitivity to radiotherapy in lung cancer cells, as previously reported by Slack’s group [25]. In this study, we observed that decreased let-7i expression was significantly associated with poorer response to chemotherapy and shorter OS of patients with GC. Since survival has traditionally been the gold standard for the primary endpoint of clinical trials of cancer therapies [26,27], and pathologic tumor regression grade is closely correlated with actual oncologic outcomes [28], our results strongly suggest that let-7i might be a novel therapeutic target for modulating chemotherapeutically sensitive and a potent biomarker for predicting tumor response and survival in advanced GC patients.

The molecular genetic basis of carcinogenesis, cancer progression and drug resistance is complex. Previous research has already discovered a variety of molecules targeted by the let-7 family and involved in its tumor suppression function. First, several well-characterized oncogenes, such as RAS [29], MYC [30], IMP1 [31], HMGA2 [32], NF2 [22], E2F2, and CCND2 [33], have been confirmed as targets of human let-7. In addition, microarray experiments have also identified a large set of cell-cycle-associated genes that are responsive to regulation of let-7 levels. Although some of these effects might be indirect, at least two genes, CDC25A and CDK6, have been found to have a direct modulation by let-7 at cell level in subsequent analysis [34]. Finally, Chen et al. reported that let-7i could regulate toll-like receptor 4 expression and contribute to cholangiocyte apoptosis responses against Cryptosporidium parvum infection [35]. Some useful targets have been identified during the past few years; however, there is no ‘one-to-one’ connection between miRNAs and target mRNAs. An average miRNA may have more than 100 targets, and one mRNA might be regulated by a variety of miRNAs. Therefore, the effect of let-7i on cancer development and chemoresistance is still not well understood, and the determination of more molecular characteristics of let-7i remains an important aim of future investigations.

**Conclusion**

In conclusion, we revealed different let-7i expression between GC and paired non-tumorous tissues. A low level of let-7i was also associated with tumor progression, chemotherapy resistance, and shorter OS. These findings indicate that let-7i may be a good candidate for use as a therapeutic target and a potential tissue marker for the prediction of chemotherapeutic sensitivity and prognosis in LAGC patients.

**Abbreviations**

ANOVA: analysis of variance; AJCC: American Joint Committee for Cancer; Ct: threshold cycle; CT: Computed Tomography; ECOG: Eastern Cooperative Oncology Group; GC: Gastric Cancer; HR: Hazard Ratio; LAGC: Locally Advanced Gastric Cancer; LN: Lymph Node; miRNA: microRNA; NAT: Normal Adjacent Tissue; OS: Overall Survival; TNM: Tumor Node Metastasis; UTR: Untranslated Regions.

**Competing interests**

The authors had no conflicts of interest to declare in relation to this article.

**Authors’ contributions**

KL and TQ carried out the molecular genetic studies, participated in the sequence alignment, and drafted the manuscript. JW and JR carried out the immunohassays. HHY participated in the sequence alignment. LMT participated in the design of the study and performed the statistical analysis. KL and LMT conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

**Author details**

1. GBHRC, 2400 N Lake Shore Dr, Cleveland, OH 44115, USA. 2. Department of General Surgery, Changzhou No. 2 Hospital, Nanjing Medical University, Nanjing, China. 3. Department of General Surgery, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China.

**Received:** 1 July 2012 **Accepted:** 15 October 2012

**Published:** 29 October 2012

**References**

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106–130.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241:27–39.
3. Cunningham D, Allum WH, Stennings SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iverson TM, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ: MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006, 355:21–30.
4. Gabrous J: The functions of animal microRNAs. Nature 2004, 431:350–355.
5. de Moor CH, Meijer H, Lissenden S: Mechanisms of translational control by the 3′ UTR in development and differentiation. Semin Cell Dev Biol 2005, 16:49–58.
6. Galin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involving in cancers. Proc Natl Acad Sci USA 2005, 102:2999–3004.
7. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944–13949.
8. O'Donnell KA, Wentzel EA, Zeller KL, Dang CV, Mitchell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839–843.
9. Johnson SM, Großhans S, Shingara J, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM: RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635–647.
10. Kováčová V, Flikovský J, Mesery J, Illytsky V, Tryndyk V, Chekun VF, Pogribny IP: Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008, 7:2152–2159.
11. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, Kamath SG, Chen DT, Dressman H, Lancaster JM: MicroRNAs and their target messenger.
RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 2009, 113:249–255.

12. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, Xu L: Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 8:266.

13. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminien A, Deng S, Smith L, Johnstone RN, Liu XM, Liu CG, Huang Q, Katsaros D, Calin GA, Weber BL, Büttzow R, Croce CM, Coukos G, Zhang L: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008, 68:10307–10314.

14. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403:901–906.

15. Takamizawa J, Kondoh H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nomiura Y, Mitusomi T, Takahashi T: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004, 64:3753–3756.

16. Yanaihara N, Caplen N, Bowman E, Seike M, Kumatomo K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189–198.

17. Akao Y, Nakagawa Y, Nae T: let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006, 29:903–906.

18. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, Weinstein JN, Sadee W: MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008, 7:1–9.

19. Fleming ID: American Joint Committee on Cancer, American Cancer Society, American College of Surgeons: AJCC Cancer Staging Manual. 5th edition. Philadelphia: Lippincott-Raven; 1997.

20. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1100–1108.

21. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003, 98:1521–1530.

22. Meng F, Henson R, Wehbe-Janek P, Smith H, Ueno Y, Patel T: The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocarcinocytes. J Biol Chem 2007, 282:8256–8264.

23. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H: Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 2007, 67:10117–10122.

24. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109–1123.

25. Weidhaas JB, Babar I, Nallur SM, Trang P, Rouash S, Boehm M, Gillespie E, Slack FJ: MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res 2007, 67:11111–11116.

26. Rubinstein LV: Therapeutic studies. Hematol Oncol Clin North Am 2000, 14:849–876.

27. Schuetze SM, Baker LH, Benjamin RS, Canetta R: Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008, 13(Suppl 2):92–40.

28. Chapet O, Romestaing P, Monnex F, Squyres JC, Favrel V, Ardiet JM, d’Hombres A, Gerard JP: Preoperative radiotherapy for rectal adenocarcinoma: which are strong prognostic factors? Int J Radiat Oncol Biol Phys 2005, 61:1371–1377.

29. Kumar MS, Efreland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T: Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 2008, 105:3903–3908.

30. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, Petrelli NJ, Dunn SP, Kuebler UJ: MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007, 67:9762–9770.

31. Boyerinas B, Park SM, Shomron N, Hedegaard MM, Vinther J, Andersen JS, Feig C, Xu J, Burge CB, Peter ME: Identification of let-7-regulated oncofetal genes. Cancer Res 2008, 68:2587–2591.

32. Lee YS, Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007, 21:1025–1036.

33. Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F, Yuan J, Chen Z, Yang A, Wang H: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting EZF2 and CCND2. PLoS One 2010, 5:e10147.

34. Johnson CD, Esqueda-Kerscher A, Stefani G, Byrom M, Kelner K, Ovcharenko D, Wilson M, Wang X, Shetton J, Shingara J, Cin H, Brown D, Slack FJ: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007, 67:7713–7722.

35. Chen XM, Splinter PL, O’Hara SP, LaRusso NF: A cellular micro-RNA, let-7i, regulates toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem 2007, 282:28929–28938.

Cite this article as: Liu et al.: Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World Journal of Surgical Oncology 2012 10:225.